By analyzing survival data of a large group of breast cancer patients, we have recently concluded that ADAM12 is the primary protease responsible for the activation of EGF receptor in early stage, lymph node-negative triple negative breast cancer (lacking the expression of estrogen receptor, progesterone receptor, and HER2) [42]. Here, ADAM12 is linked to breast cancer.